Prognostic role of proliferating CD8


Journal

Cellular oncology (Dordrecht)
ISSN: 2211-3436
Titre abrégé: Cell Oncol (Dordr)
Pays: Netherlands
ID NLM: 101552938

Informations de publication

Date de publication:
Aug 2021
Historique:
accepted: 02 03 2021
pubmed: 18 4 2021
medline: 11 1 2022
entrez: 17 4 2021
Statut: ppublish

Résumé

Expansion of CD8 To understand the CD8 The density and the percentage of proliferating (Ki67 Our data demonstrate a tumor type dependent prognostic impact of proliferating (Ki67

Identifiants

pubmed: 33864611
doi: 10.1007/s13402-021-00601-4
pii: 10.1007/s13402-021-00601-4
pmc: PMC8338812
doi:

Substances chimiques

Ki-67 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

793-803

Informations de copyright

© 2021. The Author(s).

Références

N.C. Blessin, P. Spriestersbach, W. Li, T. Mandelkow, D. Dum, R. Simon, C. Hube-Magg, F. Lutz, F. Viehweger, M. Lennartz, C. Fraune, V. Nickelsen, W. Fehrle, C. Gobel, S. Weidemann, T. Clauditz, P. Lebok, K. Moller, S. Steurer, J.R. Izbicki, G. Sauter, S. Minner, F. Jacobsen, A.M. Luebke, F. Buscheck, D. Hoflmayer, W. Wilczak, E. Burandt, A. Hinsch, Prevalence of CD8(+) cytotoxic lymphocytes in human neoplasms. Cell. Oncol. 43, 421–430 (2020)
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pages, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoue, P. Bruneval, P.H. Cugnenc, Z. Trajanoski, W.H. Fridman, F. Pages, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006)
pubmed: 17008531 doi: 10.1126/science.1129139
J. Galon, F. Pages, F.M. Marincola, M. Thurin, G. Trinchieri, B.A. Fox, T.F. Gajewski, P.A. Ascierto, The immune score as a new possible approach for the classification of cancer. J. Transl. Med. 10, 1 (2012)
pubmed: 22214470 pmcid: 3269368 doi: 10.1186/1479-5876-10-1
P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A.N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A.J. Gutierrez, T.R. Grogan, C. Mateus, G. Tomasic, J.A. Glaspy, R.O. Emerson, H. Robins, R.H. Pierce, D.A. Elashoff, C. Robert, A. Ribas, PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)
pubmed: 25428505 pmcid: 4246418 doi: 10.1038/nature13954
W. Yao, J.C. He, Y. Yang, J.M. Wang, Y.W. Qian, T. Yang, L. Ji, The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A systematic review and meta-analysis. Sci. Rep. 7, 7525 (2017)
pubmed: 28790445 pmcid: 5548736 doi: 10.1038/s41598-017-08128-1
D.S. Chen, I. Mellman, Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017)
pubmed: 28102259 doi: 10.1038/nature21349
G.L. Beatty, W.L. Gladney, Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687–692 (2015)
pubmed: 25501578 doi: 10.1158/1078-0432.CCR-14-1860
P.S. Hegde, V. Karanikas, S. Evers, The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865–1874 (2016)
L. Galluzzi, A. Buque, O. Kepp, L. Zitvogel, G. Kroemer, Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28, 690–714 (2015)
pubmed: 26678337 doi: 10.1016/j.ccell.2015.10.012
R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, H.E. Kohrt, L. Horn, D.P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P.S. Hegde, I. Mellman, D.S. Chen, F.S. Hodi, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014)
pubmed: 25428504 pmcid: 4836193 doi: 10.1038/nature14011
S. Halle, K.A. Keyser, F.R. Stahl, A. Busche, A. Marquardt, X. Zheng, M. Galla, V. Heissmeyer, K. Heller, J. Boelter, K. Wagner, Y. Bischoff, R. Martens, A. Braun, K. Werth, A. Uvarovskii, H. Kempf, M. Meyer-Hermann, R. Arens, M. Kremer, G. Sutter, M. Messerle, R. Forster, In vivo killing capacity of cytotoxic T cells is limited and involves dynamic interactions and T cell Cooperativity. Immunity 44, 233–245 (2016)
S.E. Stanton, M.L. Disis, Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J. Immunother. Cancer 4, 59 (2016)
pubmed: 27777769 pmcid: 5067916 doi: 10.1186/s40425-016-0165-6
M. Uso, E. Jantus-Lewintre, R.M. Bremnes, S. Calabuig, A. Blasco, E. Pastor, I. Borreda, S. Molina-Pinelo, L. Paz-Ares, R. Guijarro, M. Martorell, J. Forteza, C. Camps, R. Sirera, Analysis of the immune microenvironment in resected non-small cell lung cancer: The prognostic value of different T lymphocyte markers. Oncotarget 7, 52849–52861 (2016)
pubmed: 27463005 pmcid: 5288153 doi: 10.18632/oncotarget.10811
R.D. Gartrell, D.K. Marks, T.D. Hart, G. Li, D.R. Davari, A. Wu, Z. Blake, Y. Lu, K.N. Askin, A. Monod, C.L. Esancy, E.C. Stack, D.T. Jia, P.M. Armenta, Y. Fu, D. Izaki, B. Taback, R. Rabadan, H.L. Kaufman, C.G. Drake, B.A. Horst, Y.M. Saenger, Quantitative analysis of immune infiltrates in primary melanoma. Cancer Immunol. Res. 6, 481–493 (2018)
pubmed: 29467127 pmcid: 5882545 doi: 10.1158/2326-6066.CIR-17-0360
Y. Naito, K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji, H. Nagura, H. Ohtani, CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491–3494 (1998)
pubmed: 9721846
O. Nakano, M. Sato, Y. Naito, K. Suzuki, S. Orikasa, M. Aizawa, Y. Suzuki, I. Shintaku, H. Nagura, H. Ohtani, Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res. 61, 5132–5136 (2001)
pubmed: 11431351
N.A. Giraldo, E. Becht, F. Pages, G. Skliris, V. Verkarre, Y. Vano, A. Mejean, N. Saint-Aubert, L. Lacroix, I. Natario, A. Lupo, M. Alifano, D. Damotte, A. Cazes, F. Triebel, G.J. Freeman, M.C. Dieu-Nosjean, S. Oudard, W.H. Fridman, C. Sautes-Fridman, Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015)
T. Chiba, H. Ohtani, T. Mizoi, Y. Naito, E. Sato, H. Nagura, A. Ohuchi, K. Ohuchi, K. Shiiba, Y. Kurokawa, S. Satomi, Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br. J. Cancer 91, 1711–1717 (2004)
pubmed: 15494715 pmcid: 2410024 doi: 10.1038/sj.bjc.6602201
J. Gerdes, U. Schwab, H. Lemke, H. Stein, Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31, 13–20 (1983)
pubmed: 6339421 doi: 10.1002/ijc.2910310104
A. Soares, L. Govender, J. Hughes, W. Mavakla, M. de Kock, C. Barnard, B. Pienaar, E. Janse van Rensburg, G. Jacobs, G. Khomba, L. Stone, B. Abel, T.J. Scriba, W.A. Hanekom, Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J. Immunol. Methods 362, 43–50 (2010)
pubmed: 20800066 pmcid: 2989440 doi: 10.1016/j.jim.2010.08.007
N. Zhang, M.J. Bevan, CD8(+) T cells: Foot soldiers of the immune system. Immunity 35, 161–168 (2011)
pubmed: 21867926 pmcid: 3303224 doi: 10.1016/j.immuni.2011.07.010
K. Imaizumi, T. Suzuki, M. Kojima, M. Shimomura, N. Sakuyama, Y. Tsukada, T. Sasaki, Y. Nishizawa, A. Taketomi, M. Ito, T. Nakatsura, Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Sci. 111, 23–35 (2020)
pubmed: 31660687 doi: 10.1111/cas.14223
W. Shah, X. Yan, L. Jing, Y. Zhou, H. Chen, Y. Wang, A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell. Mol. Immunol. 8, 59–66 (2011)
pubmed: 21200385 doi: 10.1038/cmi.2010.56
J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter, O.P. Kallioniemi, Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844–847 (1998)
pubmed: 9662379 doi: 10.1038/nm0798-844
S. Tippmann, Programming tools: Adventures with R. Nature 517, 109–110 (2015)
pubmed: 25557714 doi: 10.1038/517109a
R-Core-Team, R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ . (2018). Accessed 01.12.2019
X. Hu, Y.Q. Li, Q.G. Li, Y.L. Ma, J.J. Peng, S.J. Cai, ITGAE defines CD8+ tumor-infiltrating lymphocytes predicting a better prognostic survival in colorectal Cancer. EBioMedicine 35, 178–188 (2018)
pubmed: 30100393 pmcid: 6154785 doi: 10.1016/j.ebiom.2018.08.003
G.E. Idos, J. Kwok, N. Bonthala, L. Kysh, S.B. Gruber, C. Qu, The prognostic implications of tumor infiltrating lymphocytes in colorectal cancer: A systematic review and meta-analysis. Sci. Rep. 10, 3360 (2020)
Y. Mao, Q. Qu, X. Chen, O. Huang, J. Wu, K. Shen, The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. PLoS One 11, e0152500 (2016)
J.S. Lee, H.S. Won, S. Sun, J.H. Hong, Y.H. Ko, Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. Medicine (Baltimore) 97, e11769 (2018)
doi: 10.1097/MD.0000000000011769
J. Li, J. Wang, R. Chen, Y. Bai, X. Lu, The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer. Oncotarget 8, 15621–15631 (2017)
pubmed: 28152503 pmcid: 5362510 doi: 10.18632/oncotarget.14919
F. Guo, Y. Dong, Q. Tan, J. Kong, B. Yu, Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: A meta-analysis. Dis. Markers 2020, 1805764 (2020)
X. Zheng, X. Song, Y. Shao, B. Xu, W. Hu, Q. Zhou, L. Chen, D. Zhang, C. Wu, J. Jiang, Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: A meta-analysis. Cell. Physiol. Biochem. 45, 720–732 (2018)
Y. Masugi, T. Abe, A. Ueno, Y. Fujii-Nishimura, H. Ojima, Y. Endo, Y. Fujita, M. Kitago, M. Shinoda, Y. Kitagawa, M. Sakamoto, Characterization of spatial distribution of tumor-infiltrating CD8(+) T cells refines their prognostic utility for pancreatic cancer survival. Mod. Pathol. 32, 1495–1507 (2019)
pubmed: 31186528 doi: 10.1038/s41379-019-0291-z
T.A. Barnes, E. Amir, HYPE or HOPE: The prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 117, 451–460 (2017)
pubmed: 28704840 pmcid: 5558691 doi: 10.1038/bjc.2017.220
Reiswich, N. Blessin, A. Rolschewski, F. Lutz, T. Mandelkow, W. Li, W. Yang, R. Simon, F. Büscheck, R. Uhlig, L. Wölber, S. Mahner, N. De Gregorio, R. Klapdor, M. Kalder, S. Steurer, W. Wilczak, C. Fraune and E. Burandt, T cell density at the invasive margin and immune phenotypes predict patient’s outcome in vulvar carcinomas, Unpublished (2021) 
N.C. Blessin, R. Abu-Hashem, T. Mandelkow, W. Li, R. Simon, C. Hube-Magg, C. Möller-Koop, M. Witt, F. Büscheck, C. Fraune, A.M. Luebke, K. Möller, J. Jacobsen, F. Lutz, M. Lennartz, S. Steurer, G. Sauter, D. Höflmayer, M.C. Tsourlakis, A. Hinsch, E. Burandt, W. Wilczak, S. Minner and T. Clauditz, Prevalence of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer, Unpublished (2021) 
R.L. Giuntoli 2nd, J. Lu, H. Kobayashi, R. Kennedy, E. Celis, Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin. Cancer Res. 8, 922–931 (2002)
pubmed: 11895927
M. Motamedi, L. Xu, S. Elahi, Correlation of transferrin receptor (CD71) with Ki67 expression on stimulated human and mouse T cells: The kinetics of expression of T cell activation markers. J. Immunol. Methods 437, 43–52 (2016)
pubmed: 27555239 doi: 10.1016/j.jim.2016.08.002
A.O. Kamphorst, R.N. Pillai, S. Yang, T.H. Nasti, R.S. Akondy, A. Wieland, G.L. Sica, K. Yu, L. Koenig, N.T. Patel, M. Behera, H. Wu, M. McCausland, Z. Chen, C. Zhang, F.R. Khuri, T.K. Owonikoko, R. Ahmed, S.S. Ramalingam, Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. U. S. A. 114, 4993–4998 (2017)
pubmed: 28446615 pmcid: 5441721 doi: 10.1073/pnas.1705327114
A. Maity, R. Mick, A.C. Huang, S.M. George, M.D. Farwell, J.N. Lukens, A.T. Berman, T.C. Mitchell, J. Bauml, L.M. Schuchter, M. O'Hara, L.L. Lin, A. Demichele, J.P. Christodouleas, N.B. Haas, D.M. Patsch, S.M. Hahn, A.J. Minn, E.J. Wherry, R.H. Vonderheide, A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br. J. Cancer 119, 1200–1207 (2018)
pubmed: 30318516 pmcid: 6251028 doi: 10.1038/s41416-018-0281-9
M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, D.E. White, S.A. Rosenberg, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009)
pubmed: 19423728 pmcid: 2927090 doi: 10.1182/blood-2008-12-195792
A.P. Ganesan, J. Clarke, O. Wood, E.M. Garrido-Martin, S.J. Chee, T. Mellows, D. Samaniego-Castruita, D. Singh, G. Seumois, A. Alzetani, E. Woo, P.S. Friedmann, E.V. King, G.J. Thomas, T. Sanchez-Elsner, P. Vijayanand, C.H. Ottensmeier, Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat. Immunol. 18, 940–950 (2017)
pubmed: 28628092 pmcid: 6036910 doi: 10.1038/ni.3775
X. Liu, R.M. Gibbons, S.M. Harrington, C.J. Krco, S.N. Markovic, E.D. Kwon, H. Dong, Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology 2, e23972 (2013)
pubmed: 23894697 pmcid: 3716732 doi: 10.4161/onci.23972
E.D. Thompson, H.L. Enriquez, Y.X. Fu, V.H. Engelhard, Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207, 1791–1804 (2010)
pubmed: 20660615 pmcid: 2916130 doi: 10.1084/jem.20092454
S.J. Golby, C. Chinyama, J. Spencer, Proliferation of T-cell subsets that contact tumour cells in colorectal cancer. Clin. Exp. Immunol. 127, 85–91 (2002)
pubmed: 11882037 pmcid: 1906282 doi: 10.1046/j.1365-2249.2002.01730.x
V. Golubovskaya and L. Wu, Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy, Cancers (Basel) 8, 36 (2016)
B. Mlecnik, G. Bindea, H.K. Angell, M.S. Sasso, A.C. Obenauf, T. Fredriksen, L. Lafontaine, A.M. Bilocq, A. Kirilovsky, M. Tosolini, M. Waldner, A. Berger, W.H. Fridman, A. Rafii, V. Valge-Archer, F. Pages, M.R. Speicher, J. Galon, Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med. 6, 228ra237 (2014)
doi: 10.1126/scitranslmed.3007240
M.L. Eich, A. Chaux, M.A. Mendoza Rodriguez, G. Guner, D. Taheri, M.D.C. Rodriguez Pena, R. Sharma, M.E. Allaf, G.J. Netto, Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma. Histopathology 76, 423–432 (2020)
pubmed: 31494951 doi: 10.1111/his.13987
J.M. Kim, D.S. Chen, Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann. Oncol. 27, 1492–1504 (2016)
pubmed: 27207108 doi: 10.1093/annonc/mdw217
S. Edin, T. Kaprio, J. Hagstrom, P. Larsson, H. Mustonen, C. Bockelman, K. Strigard, U. Gunnarsson, C. Haglund, R. Palmqvist, The prognostic importance of CD20(+) B lymphocytes in colorectal Cancer and the relation to other immune cell subsets. Sci. Rep. 9, 19997 (2019)
pubmed: 31882709 pmcid: 6934737 doi: 10.1038/s41598-019-56441-8
R. Matkowski, I. Gisterek, A. Halon, A. Lacko, K. Szewczyk, U. Staszek, M. Pudelko, B. Szynglarewicz, J. Szelachowska, A. Zolnierek, J. Kornafel, The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 29, 2445–2451 (2009)
pubmed: 19596912
B. Shang, Y. Liu, S.J. Jiang, Y. Liu, Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: A systematic review and meta-analysis. Sci. Rep. 5, 15179 (2015)
pubmed: 26462617 pmcid: 4604472 doi: 10.1038/srep15179

Auteurs

Niclas C Blessin (NC)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Wenchao Li (W)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Tim Mandelkow (T)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Hannah L Jansen (HL)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Cheng Yang (C)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Jonas B Raedler (JB)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.
College of Arts and Sciences, Boston University, Boston, MA, USA.

Ronald Simon (R)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany. r.simon@uke.de.

Franziska Büscheck (F)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

David Dum (D)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Andreas M Luebke (AM)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Andrea Hinsch (A)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Katharina Möller (K)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Anne Menz (A)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Christian Bernreuther (C)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Patrick Lebok (P)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Till Clauditz (T)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Guido Sauter (G)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Andreas Marx (A)

Institute of Pathology, Medical Centre Fürth, D-90766, Fürth, Germany.

Ria Uhlig (R)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Waldemar Wilczak (W)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Sarah Minner (S)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Till Krech (T)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Christoph Fraune (C)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Doris Höflmayer (D)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Eike Burandt (E)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Stefan Steurer (S)

Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Martinistraße 52, D-20246, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH